Study Suggests CT-Guided Injections May Restore Sense of Smell in Patients with Long COVID
Utilizing computed tomography (CT) guidance, researchers have found that performing a minimally invasive anesthetic injection into the stellate ganglia may help address parosmia due to COVID-19, according to study results that will be presented at the annual Radiological Society of North America (RSNA) conference next week.
One of the more commonly known symptoms of COVID-19 is an altered sense of smell, which may linger for months and possibly years among those with Long COVID. However, an emerging computed tomography (CT)-guided and minimally invasive procedure may provide some relief from this condition referred to as parosmia.
In a recent study, which will be presented next week at annual Radiological Society of North America (RSNA) conference in Chicago, researchers assessed the use of a CT-guided stellate ganglion block to stimulate the regional autonomic nervous system. The cohort was comprised of 54 patients referred from an ear, nose, and throat specialist with at least six months of post-COVID parosmia that failed topical and pharmaceutical treatments.
In follow-up data of the 10-minute minimally invasive procedure for 37 patients, 22 patients had improved symptoms one week after the stellate ganglion injection with 18 of those patients reporting significant improvement at one month, according to the researchers. They also noted a mean improvement of 49 percent in parosmia symptoms at three months.
In follow-up data of the stellate ganglion block injection for 37 patients, 22 patients had improved symptoms one week after the injection with 18 of those patients reporting significant improvement at one month, according to the researchers. (Image courtesy of RSNA.)
"The initial patient had a tremendously positive outcome, almost immediately, with continued improvement to the point of symptom resolution at four weeks," noted Adam C. Zoga, M.D., M.B.A., an associate professor of radiology and vice chair for clinical practice at Thomas Jefferson University in Philadelphia. "We have been surprised at some outcomes, including near 100% resolution of phantosmia in some patients, throughout the trial."
The study authors noted that 26 patients in the cohort returned for a contralateral injection approximately six weeks after the first stellate ganglion injection and conceded that it was not effective for those who reported no symptom relief from the first injection.
However, Dr. Zoga pointed out that 86 percent of patients who did respond to the first injections received additional symptom relief with the contralateral injection.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
